Business Wire

FPT and De Heus Partner to Elevate Security Operations in High-Tech Agribusiness

25.3.2024 11:06:00 EET | Business Wire | Press release

Share

Global IT corporation FPT and De Heus recently entered a strategic partnership to foster the agriculture giant's security operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320729005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

De Heus Vietnam COO Rick van der Linden (L) and FPT Software Europe CEO Tran Van Dung (R) at the signing ceremony attended by senior leaders of the Netherlands government during the economic mission to Vietnam (Photo: Business Wire)

The two firms will join forces to support De Heus’ Security Operations Center, focusing on the scope of Security Information and Event Management (SIEM). Leveraging FPT's prowess in technology and high-quality workforce, this movement will bolster De Heus’ capabilities in terms of system monitoring, security breach detection, and defense measures to effectively mitigate cyber risk and safeguard its information system and security data on a global scale.

The partnership marks a significant milestone for De Heus' digital transformation strategy amid rising cyberattack concerns in the manufacturing and agriculture industries. Both parties expect this to set a solid foundation for future collaborations in other areas like artificial intelligence, machine learning, big data, and more to further advance De Heus' and the agriculture industry's growth.

Tran Van Dung, Chief Executive Officer of FPT Software Europe, said: “While all businesses want to scale their digital transformation initiatives quickly, doing so securely is equally imperative in the face of cyber threats. Leveraging our extensive expertise and demonstrated success in deploying SIEM projects for multinational corporations globally, we stand ready to optimize De Heus' security operations.”

Rick van der Linden, Chief Operating Officer of De Heus Viet Nam, shared: “Through this partnership, FPT and De Heus are committing to leveraging our collective expertise and resources to develop robust security frameworks that will withstand the test of time. Together, we will explore innovative solutions and best practices to enhance cybersecurity measures and protect against emerging threats.”

The signing ceremony was attended by the Netherlands Minister of Infrastructure and Water Management, Mark Harbers; Minister of Agriculture, Nature, and Food Quality, Christianne van der Wal; Chair of the Confederation of Netherlands Industry and Employers, Ingrid Thijssen; and over 140 large enterprises from the Netherlands in pivotal fields of high-tech manufacturing, sustainable agriculture and food production, renewable energy, logistics, and climate adaptation and water.

Established its first office in 2008 in France, FPT has expanded its presence to 16 offices across 9 countries, serving over 70 leading businesses across Europe. Over the past decade, the tech firm has also been actively intensifying its local footprint and delivery capabilities through partnerships and acquisitions ventures, notably with the acquisition of RWE IT Slovakia, a subsidiary of European energy giant RWE in 2014, and the French IT Consulting Firm AOSIS in 2023.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 73,000 employees. For more information, please visit https://fpt.com.vn/en.

About De Heus

De Heus Vietnam, a member of Royal De Heus Group, has been proud to be Vietnam's leading animal feed supplier since 2008. De Heus provides farmers comprehensive nutritional solutions to help improve livestock productivity and product quality. With a team of experienced experts and a modern factory system, De Heus is committed to providing high-quality animal feed for all types of animals, from livestock, poultry, and aquaculture to pets. De Heus' reputable brands, such as De Heus, Windmill, Koudijs, Con Cò, and Anco, have become familiar to Vietnamese farmers. De Heus always accompanies Vietnamese farmers, aiming towards developing a sustainable and prosperous agriculture.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye